The 4th floor of the new South Pavilion at Duke Raleigh Hospital will be utilized primarily for surgical oncology inpatients.
Grand Opening: Duke Raleigh Hospital Expands with "South Pavilion"
Published
From the Duke Cancer Institute archives. Content may be out of date.
Duke Raleigh Hospital has announced the completion of its South Pavilion, an extension of the existing hospital (the North Pavilion). The multi-million dollar project allows Duke Raleigh Hospital to make the necessary advancements for its patients, their loved ones, and each other as the community grows and its health needs evolve. When the more than 210,000 square foot South Pavilion opens to its first inpatients on July 12, it will include:
92 private inpatient rooms, including 28 ICU and 64 acute care
9 state of the art operating rooms with an expanded sterile processing department
Family Waiting Areas overlooking Wake Forest Road on each inpatient floor.
An outdoor courtyard with dining areas and a walking path that connects to the Surgical Services waiting area and the new cafe.
A new kitchen and cafe offering a variety of culinary flavors and seating for close to 200 guests
Artwork by regional artists
“The newly completed South Pavilion has added space, not just for innovative care, but more room for families to be involved in the process of care during their stay here,” said Leigh Bleecker, interim president, Duke Raleigh Hospital. “The modern, welcoming look of the South Pavilion was a key part of the design. The building really allows Duke Raleigh Hospital to create a healing space for our community that embraces all the ways in which our mind, body, and spirit can be restored.”
Duke Raleigh Hospital will host a virtual grand opening ceremony for the new "South Pavilion" from 1 to 1:30 p.m. on Thursday, July 8. All members of the community are invited to join the ceremony.
We are pleased to announce that David Tuveson, MD, PhD, will join Duke Health as executive director of the Duke Cancer Institute (DCI), effective October 31, 2026.Dr. Tuveson, a preeminent cancer biologist, is currently the Roy J. Zuckerberg Professor of Cancer Research and director of the National Cancer Institute-Designated Cancer Center at Cold Spring Harbor Laboratory. He is also the chief scientist for the Lustgarten Foundation for Pancreatic Cancer Research.Dr. Tuveson is known for developing the first mouse and organoid models of pancreatic cancer and identifying subtypes of cancer-associated fibroblasts. Since developing the first mouse model of pancreatic cancer in 2002, discoveries by his lab team have revealed the molecular drivers of this disease and have led to promising new treatment options. Their approaches include designing new organoid model systems of disease and developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings.In honor of his groundbreaking research, Dr. Tuveson was awarded the Rita Allen Foundation Scholar Award, the Luminary Award from the Ruesch Center for the Cure of Gastrointestinal Cancers, the Distinguished Scholar Award from the Lustgarten Foundation, and the Hamdan Award for Medical Research Excellence. In 2022, he was on Clarivate’s list of the most cited researchers. Dr. Tuveson was elected a member of the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society for Clinical Investigation, and the Association of American Physicians. He is also a Fellow of the Academy of the American Association for Cancer Research (AACR), was elected to the AACR Board of Directors in 2018, and he served as AACR president from 2021 to 2022.As executive director, Dr. Tuveson will lead the DCI, one of the nation's premier cancer centers and a National Cancer Institute-designated comprehensive cancer center. For more than 50 years, the DCI has been at the forefront of cancer research and care, bringing together more than 400 researchers and physicians to advance discoveries and treatments that improve the lives of patients across North Carolina and beyond.We want to again express our profound gratitude to Michael Kastan, MD, PhD, DCI’s inaugural executive director and William and Jane Shingleton Distinguished Professor of Pharmacology and Cancer Biology. Dr. Kastan’s visionary leadership during his 13 years at the helm of DCI helped transform the institute into a national model for cancer programs while expanding research, multidisciplinary care, and community impact.Following Dr. Kastan's service, Erik Sulman, MD, PhD, chair of the Department of Radiation Oncology, assumed leadership of the DCI as interim executive director. We are grateful for Dr. Sulman's steady leadership in guiding DCI through this transition and maintaining momentum across its missions.We are also grateful to the search committee, led by Kathleen Ann Cooney, MD, chair of the Department of Medicine and George Barth Geller Distinguished Professor of Medicine, whose thoughtful work helped identify an exceptional leader through a national search.We are excited to begin this next chapter for DCI under Dr. Tuveson’s extraordinary research innovation and leadership. Please join us in welcoming him to the Duke Health community.
We are pleased to announce that David Tuveson, MD, PhD, will join Duke Health as executive director of the Duke Cancer Institute (DCI), effective October 31, 2026.Dr. Tuveson, a preeminent cancer biologist, is currently the Roy J. Zuckerberg Professor of Cancer Research and director of the National Cancer Institute-Designated Cancer Center at Cold Spring Harbor Laboratory. He is also the chief scientist for the Lustgarten Foundation for Pancreatic Cancer Research.Dr. Tuveson is known for developing the first mouse and organoid models of pancreatic cancer and identifying subtypes of cancer-associated fibroblasts. Since developing the first mouse model of pancreatic cancer in 2002, discoveries by his lab team have revealed the molecular drivers of this disease and have led to promising new treatment options. Their approaches include designing new organoid model systems of disease and developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings.In honor of his groundbreaking research, Dr. Tuveson was awarded the Rita Allen Foundation Scholar Award, the Luminary Award from the Ruesch Center for the Cure of Gastrointestinal Cancers, the Distinguished Scholar Award from the Lustgarten Foundation, and the Hamdan Award for Medical Research Excellence. In 2022, he was on Clarivate’s list of the most cited researchers. Dr. Tuveson was elected a member of the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society for Clinical Investigation, and the Association of American Physicians. He is also a Fellow of the Academy of the American Association for Cancer Research (AACR), was elected to the AACR Board of Directors in 2018, and he served as AACR president from 2021 to 2022.As executive director, Dr. Tuveson will lead the DCI, one of the nation's premier cancer centers and a National Cancer Institute-designated comprehensive cancer center. For more than 50 years, the DCI has been at the forefront of cancer research and care, bringing together more than 400 researchers and physicians to advance discoveries and treatments that improve the lives of patients across North Carolina and beyond.We want to again express our profound gratitude to Michael Kastan, MD, PhD, DCI’s inaugural executive director and William and Jane Shingleton Distinguished Professor of Pharmacology and Cancer Biology. Dr. Kastan’s visionary leadership during his 13 years at the helm of DCI helped transform the institute into a national model for cancer programs while expanding research, multidisciplinary care, and community impact.Following Dr. Kastan's service, Erik Sulman, MD, PhD, chair of the Department of Radiation Oncology, assumed leadership of the DCI as interim executive director. We are grateful for Dr. Sulman's steady leadership in guiding DCI through this transition and maintaining momentum across its missions.We are also grateful to the search committee, led by Kathleen Ann Cooney, MD, chair of the Department of Medicine and George Barth Geller Distinguished Professor of Medicine, whose thoughtful work helped identify an exceptional leader through a national search.We are excited to begin this next chapter for DCI under Dr. Tuveson’s extraordinary research innovation and leadership. Please join us in welcoming him to the Duke Health community.
